Treats CMV retinitis. ANDA 203511, held by Dr Reddys. Valganciclovir Hydrochloride.
As of Nov 16, 2026, ANDA 203511 (Valganciclovir Hydrochloride), held by Dr Reddys, was first approved by FDA on Nov 4, 2014, with 5 approved supplements and 0 published complete response letters.
Valganciclovir tablet is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. Pediatric Patients Prevention of CMV disease in kidney and heart transplant patients at high risk. 1.1 Adult Patients Treatment of Cytomegalovirus (CMV) Retinitis: Valganciclovir tablets are indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 4, 2014 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Valganciclovir HydrochlorideEQ 450MG BASE · tablet;oral | Valganciclovir Hydrochloride | Rx |
| May 23, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 23, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Mar 13, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 13, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 22, 2016 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 4, 2014 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters